The interaction between MyD88 and ERK is necessary for RAS-dependent transformation and cancer cell survival. Here, the authors identify benzimidazole compound EI-52 as a disrupter of this interaction and demonstrate its therapeutic efficacy in tumours via ERK dysregulation and the induction of immunogenic cell death.
- François Virard
- Stéphane Giraud
- Isabelle Coste
